Metraipolis › archive › dc_05f031a8deeb
First-line therapy of osimertinib with chemotherapy in Chinese patients with EGFR mutation-positive non-small cell lung cancer: protocol for a multicenter,… — Europe PMC PMID:40978050
- Source
- Europe PMC (en)
- Original
- https://europepmc.org/article/MED/40978050
- DOI
- 10.3389/fonc.2025.1625714
- License (as archived)
- solo-consultazione
- Archived
- 2026-11-10T03:07:06.693Z
- SHA-256 of the archived text
82e50ac86ea28742665624c356ad832bd1cc1c2f8073cf854c6bfb0fb7f02cb4- Stable URL of this page
https://metraipolis.com/documento/dc_05f031a8deeb
How to cite
First-line therapy of osimertinib with chemotherapy in Chinese patients with EGFR mutation-positive non-small cell lung cancer: protocol for a multicenter,… — Europe PMC PMID:40978050 — Europe PMC (en), https://europepmc.org/article/MED/40978050 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_05f031a8deeb (Metraipolis archive dc_05f031a8deeb, sha256 82e50ac86ea28742665624c356ad832bd1cc1c2f8073cf854c6bfb0fb7f02cb4)
BibTeX
@misc{dc05f031a8deeb,
title = {First-line therapy of osimertinib with chemotherapy in Chinese patients with EGFR mutation-positive non-small cell lung cancer: protocol for a multicenter,… — Europe PMC PMID:40978050},
howpublished = {Europe PMC (en)},
url = {https://europepmc.org/article/MED/40978050},
note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_05f031a8deeb; sha256 82e50ac86ea28742665624c356ad832bd1cc1c2f8073cf854c6bfb0fb7f02cb4},
year = {2026}
}Archived text
The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/40978050. Agents can read the archived copy with the MCP tool read_document.